Media Articles Related to Ryzolt (Tramadol)
Painkiller Tramadol Linked to Low Blood Sugar
Source: MedicineNet Hypoglycemia Specialty [2014.12.09]
Title: Painkiller Tramadol Linked to Low Blood Sugar
Category: Health News
Created: 12/8/2014 12:00:00 AM
Last Editorial Review: 12/9/2014 12:00:00 AM
Early Imaging Unhelpful in Older Adults With New Back Pain
Source: Medscape NeurologyHeadlines [2015.03.20]
A new study provides more evidence that early routine imaging for new-onset back pain in the elderly is costly and provides no benefit.
Medscape Medical News
Early imaging for back pain in older adults not associated with better outcomes
Source: Medical Devices / Diagnostics News From Medical News Today [2015.03.20]
Older adults who had spine imaging within 6 weeks of a new primary care visit for back pain had pain and disability over the following year that was not different from similar patients who did not...
Spinal cord neurons that control pain and itch
Source: Neurology / Neuroscience News From Medical News Today [2015.03.20]
The spinal cord transmits pain signals to the brain, where they are consciously perceived.
Stepped-Care Approach to Chronic Pain Improves Function
Source: Medscape Nurses Headlines [2015.03.19]
A two-step program combining analgesics, self-management strategies, and cognitive-behavioral therapy yields lasting improvement in chronic pain and function in a trial of US veterans.
Medscape Medical News
Published Studies Related to Ryzolt (Tramadol)
Efficacy of extended-release tramadol for treatment of prescription opioid
withdrawal: a two-phase randomized controlled trial. 
whether cessation of ER tramadol produces opioid withdrawal... CONCLUSIONS: ER tramadol 200mg modestly attenuated opioid withdrawal. Mild opioid
Comparison of the analgesic effects of oral tramadol and naproxen sodium on pain
relief during IUD insertion. 
on pain during insertion of an intrauterine device (IUD)... CONCLUSION: Prophylactic analgesia using 50 mg tramadol and 550 mg naproxen,
Tramadol versus methadone for treatment of opiate withdrawal: a double-blind,
randomized, clinical trial. 
The aim of this study was to compare the efficacy and safety of tramadol versus
methadone for treatment of opiate withdrawal. Seventy patients randomly were
assigned in two groups to receive either prescribed methadone (60 mg/day) or
tramadol (600 mg/day)... Tramadol may be as effective as methadone in the
control of withdrawal and could be considered as a potential substitute for
methadone to manage opioids withdrawal.
Comparison of peritonsillar infiltration effects of ketamine and tramadol on post
tonsillectomy pain: a double-blinded randomized placebo-controlled clinical
on post tonsillectomy pain and compare the side effects... CONCLUSION: Preoperative peritonsillar infiltration of tramadol can decrease
Evaluation of analgesic efficacy of intra-articular bupivacaine, bupivacaine plus fentanyl, and bupivacaine plus tramadol after arthroscopic knee surgery. [2011.12]
PURPOSE: To compare the efficacy of intra-articular (IA) bupivacaine, bupivacaine-fentanyl, and bupivacaine-tramadol for relief of postoperative pain after arthroscopic knee surgery... CONCLUSIONS: On the primary outcome measure (VAS pain score), both bupivacaine with fentanyl and bupivacaine with tramadol were better than IA bupivacaine, and bupivacaine with fentanyl was better than that with tramadol. However, both the combinations were comparable to each other with regard to the secondary outcome measure (supplementary analgesic requirement). Thus IA bupivacaine-fentanyl appears to be the best combination for relief of postoperative pain in patients undergoing arthroscopic knee surgery, followed by IA bupivacaine-tramadol. LEVEL OF EVIDENCE: Level I, randomized controlled trial. Copyright (c) 2011 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.
Clinical Trials Related to Ryzolt (Tramadol)
CYTRAM (Cytochrome P450, Tramadol) [Recruiting]
Many methods to detect CYP2D6 poor metabolizers have been validated. Some of them are based
on phenotyping (metabolism of dextromethorphan or debrisoquine) and some others on
genotyping. Up to now, CYP2D6 pharmacogenetics has been restricted to the field of research,
in spite of poor metabolizer profile concerns 5 to 10 % of caucasian population.
Nevertheless, the polymorphism of CYP2D6 is responsible for the metabolism of many drugs,
particularly of two opioids involved in pain management: codeine and tramadol, their
metabolites representing the most effective part of the drug effect. So prescribing codeine
or tramadol in a patient poor metabolizer for the CYP2D6 is likely to be ineffective in pain
O-demethyl-tramadol, the metabolite of tramadol via CYP2D6, is important to consider because
its analgesic effect is 2 to 4 times more potent than tramadol.
The investigators propose to phenotype CYP2D6 in post-operative patients treated by tramadol
by monitoring seric concentrations of O-demethyl tramadol and tramadol to make a ratio in
comparison with genotype, and to find a threshold to determine poor metabolizers. As already
described, genotyping CYP2D6 will use a rapid detection method of the alleles implicated in
poor metabolizer status (CYP2D6*3, *4, *5 et *6) in a Caucasian population. Sampling will be
executed at two times (H24 and H48 after surgery) and only with blood (three EDTA tubes)
during the post-operative monitoring of the patients. This study is likely to include 320
post-operative patients treated with intravenous tramadol during one year in three
university hospitals centers (CHU of Caen, CrĂ©teil and Rouen).
The first aim of this study is the validation of monitoring seric concentrations of
O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor
metabolizers in therapeutic situation, comparing the result with genotyping. The finding of
a poor metabolizer status in a patient will make the choice of analgesic drugs easier,
avoiding tramadol and codeine. The final objective of this research is to be able to
determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By
a single take of blood and a rapid response, this method should be liked to improve pain
management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many
other drugs depend on this way of metabolism.
A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy [Recruiting]
Tonsillectomy is the most common pediatric surgical procedure performed in the US. The
postoperative period can be particularly painful. Codeine (usually in mixed formulation with
acetaminophen) is the most commonly prescribed opioid in the US. However, evolving data
questions its ability to provide optimal pain relief, while avoiding side effects,
especially in the postoperative setting. Tramadol may be a better option for children in the
postoperative setting due to its well-documented analgesic properties, low potential for
side effects, and excellent safety profile. Seventy-two children scheduled to undergo
tonsillectomy (with or without adenoidectomy) at Children's will be invited to participate
in a randomized, prospective, double-blinded study to evaluate the efficacy and side effects
of codeine with acetaminophen versus tramadol. Using a 10-day take-home diary, caregivers
will be asked to record daily information about their child's postoperative pain and other
core outcomes and domains as recommended in the recent consensus statement put forth by the
Pediatric Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) (McGrath et al., 2008). This study will offer new information regarding the
efficacy and side effects associated with tramadol as compared with codeine/acetaminophen
(the current practice standard) in a pediatric population.
H1: Children who receive scheduled tramadol following tonsillectomy will report better pain
control than children who receive scheduled codeine/acetaminophen.
H2: Children who receive scheduled tramadol following tonsillectomy will report fewer side
effects than children who receive scheduled codeine/acetaminophen.
Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin [Recruiting]
Tramadol is an opioid analgesic, which is widely used in the treatment of acute and
neuropathic pain. Treatment of neuropathic pain often requires a combination of pain
medications due to the complex nature of neuropathic pain and frequent inadequate response
to drug treatment. Common drugs used concomitantly with tramadol are SNRI antidepressant
duloxetine and anticonvulsants such as pregabalin. Both tramadol and duloxetine have
serotonergic effects and duloxetine has also a potential to inhibit metabolism of tramadol.
The objective of the study is to investigate the pharmacokinetics and pharmacodynamic
interaction of oral tramadol with duloxetine and pregabalin in patients with chronic
neuropathic pain due to postherpetic neuralgia or diabetic polyneuropathy. All subjects will
receive tramadol and duloxetine or tramadol and pregabalin in a randomized double-blind
order. Primary end point is O-desmethyltramadol concentration.
Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain [Recruiting]
The purpose of this study is to evaluate the analgesic efficacy of Dexketoprofen Trometamol
and Tramadol Hydrochloride given in combinations and the analgesic efficacy of each single
component in comparison to placebo on moderate to severe pain following impacted third
mandibular molar tooth extraction. Ibuprofen will be used as an active control to validate
the pain model.
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal [Recruiting]
Prescription opioid addiction is a growing public health problem and more pharmacologic
treatments are needed because current approved medications have had limited patient
acceptance (naltrexone), limited availability (methadone), and concerns about misuse and
diversion (methadone and buprenorphine). Tramadol is a currently approved medication used
to treat moderate-severe pain, and initial studies demonstrate that it may be useful for
treatment of the uncomfortable syndrome of opioid withdrawal without producing euphoric
effects. This study will determine whether two different doses of extended release tramadol
can treat opioid withdrawal and whether tramadol itself produces withdrawal after it is no